Powassan virus killed a 38-year-old liver transplant recipient in southeastern Pennsylvania, and the autopsy found it everywhere — brain, lungs, kidneys, liver — according to a report published in the CDC’s Emerging Infectious Diseases journal.
The United States logged 60 confirmed cases and 9 deaths from the tickborne virus in 2024, the report states, and neuroinvasive disease occurred in 94% of confirmed cases and 98% of fatalities.
The case, described in the December 2026 issue as an early release, matters because it documents novel histopathologic findings of disseminated Powassan virus infection with multiorgan involvement in a transplant recipient. This autopsy went further.
The woman, who had alcohol-associated cirrhosis, had received an orthotopic liver transplant just six weeks before she arrived at an emergency department with malaise, headache, fever and leukocytosis, the report states. Within days of admission she suffered multiple generalized seizures. MRI revealed hydrocephalus with rapidly progressive enhancement of the cerebellum, brainstem, white matter, cortex, leptomeninges and spinal cord.
Her doctors ruled out autoimmune causes and other viral encephalitides. A brain biopsy showed lymphocytic encephalitis without a specific infectious cause, and the procedure was complicated by hemorrhage after surgeons encountered necrotic tissue. She died after being transitioned to comfort care. Cerebrospinal fluid testing confirmed Powassan virus lineage 2 — deer tick virus — the day before her death.
Rabies ruled out before the answer
Because her decline was so rapid and the usual suspects had been excluded, rabies was initially suspected — a concern with direct consequences for other organ recipients. Testing was expedited for their safety.
Rabies IgG turned up in serum and cerebrospinal fluid, but the report attributes that to a rabies preexposure vaccination she received 16 years earlier, possibly spilling over from serum through a blood–brain barrier damaged by severe meningoencephalitis. All other antemortem and postmortem rabies tests, including immunohistochemistry and PCR of the brain and liver, came back negative.
One telling detail: an earlier cerebrospinal fluid sample sent for metagenomic sequencing was negative for Powassan virus, which the authors suggest may reflect low viral load or the limits of the test’s detection. The diagnosis landed only on a targeted PCR near the end.
What the autopsy found
The postmortem examination, detailed in the journal’s figure panels, showed a 3.2-centimeter focus of necrosis and hemorrhage in the right basal ganglia, diffuse brain edema, and widespread meningoencephalitis across the cerebrum, pons and cerebellum. But the virus had not stayed in the nervous system.
In the lungs, pathologists documented mild lymphocytic pneumonitis and bronchiolar epithelial denudation with cell apoptosis — and detected Powassan viral antigen and RNA in bronchiolar epithelial cells, pneumocytes and endothelial cells. In the kidneys, they found mononuclear infiltrates around tubules, acute tubular injury and pigmented casts, with viral antigen and RNA in renal tubular epithelial cells. Viral antigen also appeared in circulating mononuclear cells in the kidneys, lungs and liver.
That distribution matters beyond one patient. The report cites prior work on flaviviruses and kidney injury, and its authors write that impaired organ function through direct Powassan virus infection is possible.
The numbers behind the alarm
The epidemiological backdrop gives the case its urgency. The report cites CDC historic data showing 60 confirmed U.S. cases and 9 deaths during 2024, with cases increasing annually. Of confirmed cases that year, 94% were neuroinvasive; among fatalities, 98% were. Powassan virus is a tickborne flavivirus that causes severe encephalitis, and the report notes documented cases across Pennsylvania districts.
Immunocompromised patients appear disproportionately vulnerable. The authors reference prior reports of severe arboviral neuroinvasive disease in patients on rituximab therapy and of neuroinvasive West Nile virus in immunosuppressed adults.
The work itself was a collaboration: pathologists and clinicians at the Hospital of the University of Pennsylvania, including D.C. Sung, an anatomic and clinical pathology resident there; virologists at the Centers for Disease Control and Prevention in Atlanta; and investigators from the Pennsylvania Department of Health and the Chester County Health Department.
The full, final version of the study is scheduled for publication in Emerging Infectious Diseases Volume 32, Number 12, in December 2026. The early release carries the journal’s standard caveat that it is not yet considered final and may change before official release.
For clinicians, the practical lesson sits in the diagnostic sequence: metagenomic sequencing missed it, and only targeted Powassan virus PCR on cerebrospinal fluid — run the day before death — confirmed the cause.